摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-aminophenyl)-5-phenyl-3-(trifluoromethyl)pyrazole | 634188-12-8

中文名称
——
中文别名
——
英文名称
1-(4-aminophenyl)-5-phenyl-3-(trifluoromethyl)pyrazole
英文别名
4-(5-Phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)aniline;4-[5-phenyl-3-(trifluoromethyl)pyrazol-1-yl]aniline
1-(4-aminophenyl)-5-phenyl-3-(trifluoromethyl)pyrazole化学式
CAS
634188-12-8
化学式
C16H12F3N3
mdl
——
分子量
303.287
InChiKey
QTGLHUIMHLBQPM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    22
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    43.8
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    5-氯代水杨酸1-(4-aminophenyl)-5-phenyl-3-(trifluoromethyl)pyrazole 、 以the same operation as the Example 16 gave the title compound的产率得到5-chloro-2-hydroxy-N-{4-[5-phenyl-3-(trifluoromethyl)pyrazol-1-yl]phenyl}-benzamide
    参考文献:
    名称:
    Medicament for treatment of diabetes
    摘要:
    一种用于预防和/或治疗糖尿病或糖尿病并发症的药物,其活性成分为以下通式(I)所表示的化合物或其药学上可接受的盐、水合物或溶剂化物之一: 其中,X代表主链中原子数为2到5的连接基(该连接基可以被取代),A代表氢原子或乙酰基,E代表可以被取代的芳基或杂环芳基,环Z代表可以具有一个或多个取代基的芳基,除了由公式—O—A所表示的基团外,该芳基可以具有公式—X-E所表示的基团,其中每个X和E的含义与上述定义相同,或者可以具有一个或多个取代基的杂环芳基,除了由公式—O—A所表示的基团外,该杂环芳基可以具有公式—X-E所表示的基团,其中每个X和E的含义与上述定义相同。
    公开号:
    US20060111409A1
点击查看最新优质反应信息

文献信息

  • Inhibitors against the activation of ap-1 and nfat
    申请人:Muto Susumu
    公开号:US20060100257A1
    公开(公告)日:2006-05-11
    A medicament inhibiting the activation of AP-1 which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种药物,抑制AP-1的激活,其活性成分为以下通式(I)所表示的化合物或其药学上可接受的盐、水合物或溶剂化物中所选的一种,其中X代表连接基,其主链中的原子数为2至5(该连接基可以被取代),A代表氢原子或乙酰基,E代表芳基或取代的杂芳基,环Z代表芳烃,除了由式—O-A所表示的基团外,可能还有一个或多个取代基,其中A具有上述定义的相同含义,由式—X-E所表示的基团中,X和E的每一个具有上述定义的相同含义,或者是一个杂芳烃,可能还有一个或多个取代基,其中A具有上述定义的相同含义,由式—X-E所表示的基团中,X和E的每一个具有上述定义的相同含义。
  • Medicament for treatment of diabetes
    申请人:Muto Susumu
    公开号:US20060111409A1
    公开(公告)日:2006-05-25
    A medicament for preventive and/or therapeutic treatment of diabetes or complications of diabetes which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O— A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种用于预防和/或治疗糖尿病或糖尿病并发症的药物,其活性成分为以下通式(I)所表示的化合物或其药学上可接受的盐、水合物或溶剂化物之一: 其中,X代表主链中原子数为2到5的连接基(该连接基可以被取代),A代表氢原子或乙酰基,E代表可以被取代的芳基或杂环芳基,环Z代表可以具有一个或多个取代基的芳基,除了由公式—O—A所表示的基团外,该芳基可以具有公式—X-E所表示的基团,其中每个X和E的含义与上述定义相同,或者可以具有一个或多个取代基的杂环芳基,除了由公式—O—A所表示的基团外,该杂环芳基可以具有公式—X-E所表示的基团,其中每个X和E的含义与上述定义相同。
  • Antiallergic
    申请人:Muto Susumu
    公开号:US20060122243A1
    公开(公告)日:2006-06-08
    A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种用于预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物,其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分,其中X代表主链中原子数为2到5的连接基(该连接基可以被取代),A代表氢原子或乙酰基,E代表可以被取代的芳基或杂环芳基,环Z代表可以具有一个或多个取代基的芳烃,除了由公式-O-A所表示的基团外,该芳烃还可以具有公式—X-E所表示的基团,其中每个X和E具有上述定义的相同含义,或者该环可以具有一个或多个取代基,除了由公式—O-A所表示的基团外,该环还可以具有公式—X-E所表示的基团,其中A具有上述定义的相同含义,X和E分别具有上述定义的相同含义。
  • Immunity-related protein kinase inhibitors
    申请人:Muto Susumu
    公开号:US20060019958A1
    公开(公告)日:2006-01-26
    A medicament having an inhibitory activity against IKK-β and/or MEKK-1 or other protein kinases structurally similar thereto, which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种药物具有对IKK-β和/或MEKK-1或其他结构相似的蛋白激酶的抑制活性,其包括以下通式(I)所表示的化合物或其药学上可接受的盐,以及其水合物和溶剂化物作为活性成分的物质:其中,X表示连接主链中原子数为2至5的连接基(该连接基可以被取代),A表示氢原子或乙酰基,E表示可以被取代的芳基或取代的杂环芳基,环Z表示可以具有一个或多个取代基的芳烃,除了由式-O-A表示的基团外,该芳烃还可以具有式-X-E所表示的基团,其中每个X和E的含义与上述定义相同,或者是可以具有一个或多个取代基的杂环芳烃,除了由式-O-A表示的基团外,该杂环芳烃还可以具有式-X-E所表示的基团,其中每个X和E的含义与上述定义相同。
  • ANTIALLERGIC AGENTS
    申请人:Muto Susumu
    公开号:US20080090779A1
    公开(公告)日:2008-04-17
    A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.
    一种预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物,其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分,其中X表示连接基,其主链中原子数为2至5(该连接基可以被取代),A表示氢原子或乙酰基,E表示芳基或取代的杂芳基,环Z表示苯环,除了由公式-O-A表示的基团,该苯环还可以具有一个或多个取代基团,其中A的含义与上述定义相同,而由公式-X-E表示的基团中,每个X和E的含义也与上述定义相同,或者是一个杂环,除了由公式-O-A表示的基团,该杂环还可以具有一个或多个取代基团,其中A的含义与上述定义相同,而由公式-X-E表示的基团中,每个X和E的含义也与上述定义相同。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺